Wockhardt has received final approval from the USFDA for marketing nasal spray of Fluticasone which is used in treatment of allergic rhinitis.
This news led, to rise in the shares of the company over 4%, hitting the weekly high of Rs309.40. Uptill now, over 1.17 lakh shares have traded on the BSE as against the two-week average volume of 0.89 lakh shares.
The total market for this product in the US is about $580 million according to IMS Health, the company said.
Fluticasone nasal spray is amongst the most widely used corticosteroids in treating allergic rhinitis, it added.
....more info
This news led, to rise in the shares of the company over 4%, hitting the weekly high of Rs309.40. Uptill now, over 1.17 lakh shares have traded on the BSE as against the two-week average volume of 0.89 lakh shares.
The total market for this product in the US is about $580 million according to IMS Health, the company said.
Fluticasone nasal spray is amongst the most widely used corticosteroids in treating allergic rhinitis, it added.
....more info